Permanent Indian Bar Against Glenmark’s Sitagliptin Copies
This article was originally published in PharmAsia News
Executive Summary
An Indian court has permanently enjoined Glenmark from making and selling its generic version of Merck’s diabetes therapies Januvia and Janumet after the Indian firm was found to have infringed the sitagliptin patent.